Evidence map›Paper›PMID 39011475›Full record

ArticleFrontiers in oncology2024

Chronic myelomonocytic leukemia with ring sideroblasts/

Blanca Xicoy, Helena Pomares, Mireia Morgades, Ulrich Germing, Montserrat Arnan, Mar Tormo, Laura Palomo, Elisa Orna, Matteo Della Porta, Felicitas Schulz and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  3. Article
  4. Clinical management of CMML-State of the art.British journal of haematology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Blanca XicoyHematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.
Helena PomaresHematology Department. Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Mireia MorgadesHematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.
Ulrich GermingDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine Universitätsklinikum, Düsseldorf, Germany.
Montserrat ArnanHematology Department. Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Mar TormoHematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Laura PalomoHematology Department, Hospital Universitari Vall d'Hebró, Barcelona, Spain.
Elisa OrnaHematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.
Matteo Della PortaHematology Department, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Felicitas SchulzDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine Universitätsklinikum, Düsseldorf, Germany.
Marina Díaz-BeyaHematology Department, Hospital Clínic, Barcelona, Spain.
Ada EstebanHematology Department, Hospital de San Pedro, Logroño, Spain.
Antonieta MoleroHematology Department, Hospital Universitari Vall d'Hebró, Barcelona, Spain.
Luca LaninoHematology Department, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Alejandro AvendañoHematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
Francisca HernándezHematology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Verónica RoldanHematology Department, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain.
Marta UbezioHematology Department, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Alberto PinedaHematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.
María Díez-CampeloHematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
Lurdes ZamoraHematology Department, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Myeloid Neoplasms Group, Josep Carreras Leukemia Research Institute-Hospital Germans Trias i Pujol, Badalona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) with ring sideroblasts (RS) or Methods: We compared CMML with and without RS/ Results: A total of 815 patients were included (CMML, n=319, CMML-RS/ Discussion: CMML-RS/

Indexed as

CMMLCMML-RS/SF3B1MDS-RS/SF3B1mutational profilephenotypeprognosis

Identifiers

PMID39011475
PMCPMC11246989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.